NLS pharma-clinical-trial-box

The company has reported results from the OPTIMIZE-1 Phase 2 study of its lead asset mitazalimab in 1st line metastatic pancreatic cancer. The open-label, multi-center study assessed the safety and efficacy of mitazalimab (CD40 mAb agonist) in combination with standard of care chemotherapy mFOLFIRINOX, in previously untreated, chemotherapy naive patients. The study achieved its primary […]

The first test results from patient 1 have been received and show a very strong effect on the marker of osteoclast activity (CTX), states the company. The baseline value for CTX decreases by about 80% after 3 doses of OsteoDex. The other values are fairly constant (cf. baseline). Osteoclasts break down bone (resorb) and CTX […]

Toleranzia has announced that the toxicology study, conducted under Good Laboratory Practice (GLP), to enable first-in-human clinical trials, has been completed. The drug candidate was well tolerated at the dose tested, a finding fully supporting continued development of TOL2 and the submission of an application for the initiation of clinical trials in patients with myasthenia […]

BioInvent International has presented the first clinical data from a Phase 1/2a trial of its second FcyRIIB-blocking antibody BI-1607. BioInvent pipeline currently includes five drug candidates progressing through six clinical trials. The Phase 1 data The Phase 1 data covered 18 patients treated at doses ranging from 75 mg up to 900 mg flat dose. […]

Affibody has announced that data from treatment with izokibep in the open label part (Part A) of a Phase 2b/3 trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) will be presented. The data from the open label Part A, presented at the American Academy of Dermatology (AAD) Annual Meeting in New Orleans, USA, demonstrated that […]

Targovax has announced that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in the USA. The study is led by gastrointestinal cancer expert Dr. Anup Kasi in a three-way clinical collaboration between Kansas University Cancer Center (KUCC), Agenus […]